
    
      The overall objective of the present study is to provide proof of concept that treatment with
      the GLP-1 receptor agonist liraglutide is efficacious (as assessed by symptom relief, i.e.
      response to treatment) and safe (as assessed by adverse effects) in the management of BAM and
      that it improves bile acid reabsorption (as assessed by SeHCAT) in these patients.
    
  